Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins

Journal of Virology

Volumn 85, Issue 17, 2011, Pages 8514-8527

  Wilen, Craig B ^a   Parrish, Nicholas F ^b   Pfaff, Jennifer M ^a   Decker, Julie M ^b   Henning, Elizabeth A ^a   Haim, Hillel ^c   Petersen, Josiah E ^a   Wojcechowskyj, Jason A ^a   Sodroski, Joseph ^c   Haynes, Barton F ^d   Montefiori, David C ^d   Tilton, John C ^e   Shaw, George M ^b   Hahn, Beatrice H ^b   Doms, Robert W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b University of Alabama at Birmingham   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; ENFUVIRTIDE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIBODY COMBINING SITE; ARTICLE; BIOLOGICAL ACTIVITY; CD4+ T LYMPHOCYTE; CLADISTICS; CONTROLLED STUDY; DENDRITIC CELL; DRUG SENSITIVITY; GENETIC LINKAGE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PSEUDOTYPING; SENSITIVITY ANALYSIS; T LYMPHOCYTE SUBPOPULATION; VIRAL TROPISM; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION;

ANTIBODIES, NEUTRALIZING; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; VIRAL TROPISM; VIRUS INTERNALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80052302577     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00736-11     Document Type: Article

References (79)

1. Abrahams, M. R., et al. 2009. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-Poisson distribution of transmitted variants. J. Virol. 83:3556-3567.
2. Alexander, M., et al. 2010. Donor and recipient envs from heterosexual human immunodeficiency virus subtype C transmission pairs require high receptor levels for entry. J. Virol. 84:4100-4104.
3. Balotta, C., et al. 1997. Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS 11:F67-F71.
4. Bar, K. J., et al. 2010. Wide variation in the multiplicity of HIV-1 infection among injection drug users. J. Virol. 84:6241-6247.
5. Barbas, C. F., III, et al. 1992. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. U. S. A. 89:9339-9343.
6. Biswas, P., G. Tambussi, and A. Lazzarin. 2007. Access denied? The status of co-receptor inhibition to counter HIV entry. Expert Opin. Pharmacother. 8:923-933.
7. Bleul, C. C., L. Wu, J. A. Hoxie, T. A. Springer, and C. R. Mackay. 1997. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 94:1925-1930.
8. Borrow, P., et al. 1997. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 3:205-211.
9. Bridger, G. J., et al. 1995. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker. J. Med. Chem. 38:366-378.
10. Bunnik, E. M., et al. 2010. Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level. Nat. Med. 16:995-997.
11. Burton, D. R., et al. 1991. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. U. S. A. 88:10134-10137.
12. Burton, D. R., et al. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027.
13. Chohan, B., et al. 2005. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J. Virol. 79:6528-6531.
14. Cleghorn, F. R., et al. 2000. A distinctive clade B HIV type 1 is heterosexually transmitted in Trinidad and Tobago. Proc. Natl. Acad. Sci. U. S. A. 97:10532-10537.
15. Curlin, M. E., et al. 2010. HIV-1 envelope subregion length variation during disease progression. PLoS Pathog. 6:e1001228.
16. Dalgleish, A. G., et al. 1984. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312:763-767.
17. Decker, J. M., et al. 2005. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J. Exp. Med. 201:1407-1419.
18. De Clercq, E., et al. 1994. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob. Agents Chemother. 38:668-674.
19. Derdeyn, C. A., et al. 2004. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303:2019-2022.
20. Doores, K. J., and D. R. Burton. 2010. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J. Virol. 84:10510-10521.
21. Eckstein, D. A., et al. 2001. HIV-1 actively replicates in naive CD4(+) T cells residing within human lymphoid tissues. Immunity 15:671-682.
22. Emmelkamp, J. M., and J. K. Rockstroh. 2007. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions-review of the literature. Eur. J. Med. Res. 12:409-417.
23. Fiebig, E. W., et al. 2003. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17:1871-1879.
24. Frost, S. D., et al. 2005. Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J. Virol. 79:6523-6527.
25. Geijtenbeek, T. B., et al. 2000. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100:587-597.
26. Giorgi, J. V., et al. 1999. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J. Infect. Dis. 179:859-870.
27. Gordon, S. N., et al. 2010. Disruption of intestinal CD4+ T cell homeostasis is a key marker of systemic CD4+ T cell activation in HIV-infected individuals. J. Immunol. 185:5169-5179.
28. Groot, F., T. M. van Capel, J. Schuitemaker, B. Berkhout, and E. C. de Jong. 2006. Differential susceptibility of naive, central memory and effector memory T cells to dendritic cell-mediated HIV-1 transmission. Retrovirology 3:52.
29. Guindon, S., and O. Gascuel. 2003. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst. Biol. 52:696-704.
30. Haaland, R. E., et al. 2009. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog. 5:e1000274.
31. Haase, A. T. 2011. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu. Rev. Med. 62:127-139.
32. Haim, H., et al. 2009. Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog. 5:e1000360.
33. Harrison, J. E., et al. 2008. Baseline resistance of primary human immunodeficiency virus type 1 strains to the CXCR4 inhibitor AMD3100. J. Virol. 82:11695-11704.
34. Hendrix, C. W., et al. 2000. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob. Agents Chemother. 44:1667-1673.
35. Isaacman-Beck, J., et al. 2009. Heterosexual transmission of human immunodeficiency virus type 1 subtype C: macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization. J. Virol. 83:8208-8220.
36. Keele, B. F., et al. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 105:7552-7557.
37. Klatzmann, D., et al. 1984. Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. Science 225:59-63.
38. Lee, B., et al. 1999. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J. Biol. Chem. 274:9617-9626.
39. Li, H., et al. 2010. High multiplicity infection by HIV-1 in men who have sex with men. PLoS Pathog. 6:e1000890.
40. Li, M., et al. 2006. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J. Virol. 80:11776-11790.
41. McMichael, A. J., P. Borrow, G. D. Tomaras, N. Goonetilleke, and B. F. Haynes. 2010. The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. Immunol. 10:11-23.
42. Mehandru, S., K. Tenner-Racz, P. Racz, and M. Markowitz. 2005. The gastrointestinal tract is critical to the pathogenesis of acute HIV-1 infection. J. Allergy Clin. Immunol. 116:419-422.
43. Miyauchi, K., Y. Kim, O. Latinovic, V. Morozov, and G. B. Melikyan. 2009. HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 137:433-444.
44. Miyauchi, K., M. M. Kozlov, and G. B. Melikyan. 2009. Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation. PLoS Pathog. 5:e1000585.
45. Mo, H., et al. 1998. Expression patterns of the HIV type 1 coreceptors CCR5 and CXCR4 on CD4+ T cells and monocytes from cord and adult blood. AIDS Res. Hum. Retroviruses 14:607-617.
46. Nishimura, Y., et al. 2005. Resting naive CD4+ T cells are massively infected and eliminated by X4-tropic simian-human immunodeficiency viruses in macaques. Proc. Natl. Acad. Sci. U. S. A. 102:8000-8005.
47. O'Brien, T. R., et al. 1997. HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet 349:1219.
48. Ostrowski, M. A., et al. 1999. Both memory and CD45RA+/CD62L+ naive CD4(+) T cells are infected in human immunodeficiency virus type 1-infected individuals. J. Virol. 73:6430-6435.
49. Pang, S., et al. 1992. Rapid generation of sequence variation during primary HIV-1 infection. AIDS 6:453-460.
50. Pfaff, J. M., et al. 2010. HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells. J. Virol. 84:6505-6514.
51. Piguet, V., and R. M. Steinman. 2007. The interaction of HIV with dendritic cells: outcomes and pathways. Trends Immunol. 28:503-510.
52. Poss, M., et al. 1995. Diversity in virus populations from genital secretions and peripheral blood from women recently infected with human immunodeficiency virus type 1. J. Virol. 69:8118-8122.
53. Puffer, B. A., L. A. Altamura, T. C. Pierson, and R. W. Doms. 2004. Determinants within gp120 and gp41 contribute to CD4 independence of SIV Envs. Virology 327:16-25.
54. Reeves, J. D., et al. 2002. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc. Natl. Acad. Sci. U. S. A. 99:16249-16254.
55. Roben, P., et al. 1994. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68:4821-4828.
56. Roos, M. T., et al. 1992. Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection. J. Infect. Dis. 165:427-432.
57. Rusert, P., et al. 2005. Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J. Virol. 79:8454-8469.
58. Sagar, M., et al. 2009. Selection of HIV variants with signature genotypic characteristics during heterosexual transmission. J. Infect. Dis. 199:580-589.
59. Salazar-Gonzalez, J. F., et al. 2008. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J. Virol. 82:3952-3970.
60. Salazar-Gonzalez, J. F., et al. 2009. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J. Exp. Med. 206:1273-1289.
61. Sallusto, F., D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708-712.
62. Scarlatti, G., et al. 1997. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat. Med. 3:1259-1265.
63. Schuitemaker, H., et al. 1992. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J. Virol. 66:1354-1360.
64. Seaman, M. S., et al. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84:1439-1452.
65. Stephenson, J. 2007. Researchers buoyed by novel HIV drugs: will expand drug arsenal against resistant virus. JAMA 297:1535-1536.
66. Theodorou, I., L. Meyer, M. Magierowska, C. Katlama, and C. Rouzioux. 1997. HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group. Lancet 349:1219-1220.
67. Tilton, J. C., et al. 2010. A maraviroc-resistant HIV-1 with narrow crossresistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J. Virol. 84:10863-10876.
68. Walker, L. M., et al. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
69. Wei, X., et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312.
70. Westby, M., et al. 2007. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81:2359-2371.
71. Wolfs, T. F., G. Zwart, M. Bakker, and J. Goudsmit. 1992. HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. Virology 189:103-110.
72. Wolinsky, S. M., et al. 1992. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 255:1134-1137.
73. Wu, X., et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861.
74. Zhang, H., et al. 2004. Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J. Virol. 78:1718-1729.
75. Zhang, L. Q., et al. 1993. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J. Virol. 67:3345-3356.
76. Zhang, M., et al. 2004. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 14:1229-1246.
77. Zhang, Z., et al. 1999. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 286:1353-1357.
78. Zhou, T., et al. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329:811-817.
79. Zhu, T., et al. 1993. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261:1179-1181.